JHS Svendgaard Labs.
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
JHS Svendgaard Laboratories' board on June 25 approved further changes to how the company will use the ₹30 crore raised via a preferential issue in 2024. The earlier plan, authorised by shareholders in June 2025, earmarked ₹5.99 crore for equipment and ₹16.50 crore for infusion into group entity JHS Svendgaard Retail Ventures. The revised objects consolidate these into a ₹11.75 crore bucket for capital expenditure and business expansion and a ₹10.75 crore bucket for strategic and growth initiatives, while the ₹7.50 crore general corporate purpose component remains unchanged. The total amount of ₹30 crore stays the same, and the board said the change is primarily clarificatory, aimed at providing greater flexibility. The modification requires shareholder approval.
Powered by Tijori
JHS Svendgaard Laboratories' board on June 25 approved further changes to how the company will use the ₹30 crore raised via a preferential issue in 2024. The earlier plan, authorised by shareholders in June 2025, earmarked ₹5.99 crore for equipment and ₹16.50 crore for infusion into group entity JHS Svendgaard Retail Ventures. The revised objects consolidate these into a ₹11.75 crore bucket for capital expenditure and business expansion and a ₹10.75 crore bucket for strategic and growth initiatives, while the ₹7.50 crore general corporate purpose component remains unchanged. The total amount of ₹30 crore stays the same, and the board said the change is primarily clarificatory, aimed at providing greater flexibility. The modification requires shareholder approval.
Powered by Tijori
July 1 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
JHS SVENDGAARD LABORATORIES LTD - RE-APPOINTS NIKHIL NANDA AS MANAGING DIRECTOR FOR FIVE YEARS
Source text: ID:nBSE4vWtdQ
Further company coverage: JHSS.NS
(([email protected];;))
July 1 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
JHS SVENDGAARD LABORATORIES LTD - RE-APPOINTS NIKHIL NANDA AS MANAGING DIRECTOR FOR FIVE YEARS
Source text: ID:nBSE4vWtdQ
Further company coverage: JHSS.NS
(([email protected];;))
March 5 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
APPROVES INVESTMENT OF 50 MILLION RUPEES IN JHS SVENDGAARD RETAIL VENTURES
Source text: ID:nBSE9c4JsB
Further company coverage: JHSS.NS
(([email protected];;))
March 5 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
APPROVES INVESTMENT OF 50 MILLION RUPEES IN JHS SVENDGAARD RETAIL VENTURES
Source text: ID:nBSE9c4JsB
Further company coverage: JHSS.NS
(([email protected];;))
Sept 19 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
ACQUIRES LAND IN JAMMU & KASHMIR FOR PURPOSE OF EXPANSION
Source text for Eikon: ID:nNSE4R8jmZ
Further company coverage: JHSS.NS
(([email protected];;))
Sept 19 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
ACQUIRES LAND IN JAMMU & KASHMIR FOR PURPOSE OF EXPANSION
Source text for Eikon: ID:nNSE4R8jmZ
Further company coverage: JHSS.NS
(([email protected];;))
June 21 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
UNDERTAKEN STRATEGIC INITIATIVE TO EXPAND ITS BUSINESS OPERATIONS
DECIDED TO ESTABLISH NEW PROJECT IN JAMMU AND KASHMIR
Source text for Eikon: ID:nBSEBVdXc
Further company coverage: JHSS.NS
(([email protected];;))
June 21 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
UNDERTAKEN STRATEGIC INITIATIVE TO EXPAND ITS BUSINESS OPERATIONS
DECIDED TO ESTABLISH NEW PROJECT IN JAMMU AND KASHMIR
Source text for Eikon: ID:nBSEBVdXc
Further company coverage: JHSS.NS
(([email protected];;))
June 4 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
APPROVED ISSUE AND ALLOTMENT OF EQUITY SHARES ON PREFERENTIAL BASIS WORTH UP TO 200 MILLION RUPEES
TO ISSUE FULLY CONVERTIBLE WARRANTS ON PREFERENTIAL BASIS, AGGREGATING UPTO 100 MILLION RUPEES
Source text for Eikon: ID:nNSEbpWTwr
Further company coverage: JHSS.NS
(([email protected];;))
June 4 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
APPROVED ISSUE AND ALLOTMENT OF EQUITY SHARES ON PREFERENTIAL BASIS WORTH UP TO 200 MILLION RUPEES
TO ISSUE FULLY CONVERTIBLE WARRANTS ON PREFERENTIAL BASIS, AGGREGATING UPTO 100 MILLION RUPEES
Source text for Eikon: ID:nNSEbpWTwr
Further company coverage: JHSS.NS
(([email protected];;))
March 5 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
WITHDREW FROM SCHEME OF ARRANGEMENT FOR AMALGAMATION OF CO WITH VEDIC COSMECEUTICALS
WITHDREW DUE TO UNFORESEEN CHALLENGES IN INTEGRATION AND PRACTICAL ISSUES
SCHEME STANDS REVOKED WITH IMMEDIATE EFFECT, ALL ASSOCIATED TRANSACTIONS STAND TERMINATED ACCORDINGLY
Further company coverage: JHSS.NS
(([email protected];))
March 5 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
WITHDREW FROM SCHEME OF ARRANGEMENT FOR AMALGAMATION OF CO WITH VEDIC COSMECEUTICALS
WITHDREW DUE TO UNFORESEEN CHALLENGES IN INTEGRATION AND PRACTICAL ISSUES
SCHEME STANDS REVOKED WITH IMMEDIATE EFFECT, ALL ASSOCIATED TRANSACTIONS STAND TERMINATED ACCORDINGLY
Further company coverage: JHSS.NS
(([email protected];))
Sept 22 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
APPROVED SCHEME OF ARRANGEMENT FOR AMALGAMATION OF CO WITH VEDIC COSMECEUTICALS
Source text for Eikon: ID:nNSE8cRqXD
Further company coverage: JHSS.NS
(([email protected];))
Sept 22 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
APPROVED SCHEME OF ARRANGEMENT FOR AMALGAMATION OF CO WITH VEDIC COSMECEUTICALS
Source text for Eikon: ID:nNSE8cRqXD
Further company coverage: JHSS.NS
(([email protected];))
Aug 15 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
BOARD IN-PRINCIPALLY AGREED TO THE AMALGAMATION OF CO AND VEDIC COSMECEUTICALS
Source text for Eikon: ID:nBSE3N64H0
Further company coverage: JHSS.NS
(([email protected];))
Aug 15 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
BOARD IN-PRINCIPALLY AGREED TO THE AMALGAMATION OF CO AND VEDIC COSMECEUTICALS
Source text for Eikon: ID:nBSE3N64H0
Further company coverage: JHSS.NS
(([email protected];))
May 30 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
JHS SVENDGAARD LABORATORIES LTD - APPOINTS DEEPESH SHARMA AS JOINT CFO
Source text for Eikon: ID:nNSE4CYhp3
Further company coverage: JHSS.NS
(([email protected];))
May 30 (Reuters) - JHS Svendgaard Laboratories Ltd JHSS.NS:
JHS SVENDGAARD LABORATORIES LTD - APPOINTS DEEPESH SHARMA AS JOINT CFO
Source text for Eikon: ID:nNSE4CYhp3
Further company coverage: JHSS.NS
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does JHS Svendgaard Labs. do?
JHS Svendgaard Laboratories Limited manufactures and trades a variety of oral care products including toothbrushes, toothpastes, denture tablets, and mouthwash. They also produce laundry products and collaborate with major FMCG brands domestically and internationally.
Who are the competitors of JHS Svendgaard Labs.?
JHS Svendgaard Labs. major competitors are Naturo AgrotechIndia, Lloyds Luxuries, Radix Industries (I), Kaya, Bajaj Consumer Care, Emami, Zydus Wellness. Market Cap of JHS Svendgaard Labs. is ₹64 Crs. While the median market cap of its peers are ₹362 Crs.
Is JHS Svendgaard Labs. financially stable compared to its competitors?
JHS Svendgaard Labs. seems to be less financially stable compared to its competitors. Altman Z score of JHS Svendgaard Labs. is 2.02 and is ranked 6 out of its 8 competitors.
Does JHS Svendgaard Labs. pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. JHS Svendgaard Labs. latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has JHS Svendgaard Labs. allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is JHS Svendgaard Labs. balance sheet?
Balance sheet of JHS Svendgaard Labs. is moderately strong.
Is the profitablity of JHS Svendgaard Labs. improving?
The profit is oscillating. The profit of JHS Svendgaard Labs. is -₹1.92 Crs for TTM, -₹19.74 Crs for Mar 2025 and -₹4.06 Crs for Mar 2024.
Is the debt of JHS Svendgaard Labs. increasing or decreasing?
Yes, The net debt of JHS Svendgaard Labs. is increasing. Latest net debt of JHS Svendgaard Labs. is -₹4.29 Crs as of Mar-26. This is greater than Mar-25 when it was -₹33.94 Crs.
Is JHS Svendgaard Labs. stock expensive?
JHS Svendgaard Labs. is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of JHS Svendgaard Labs. is 0, while 3 year average PE is 5.72. Also latest EV/EBITDA of JHS Svendgaard Labs. is 22.82 while 3yr average is 13.43.
Has the share price of JHS Svendgaard Labs. grown faster than its competition?
JHS Svendgaard Labs. has given lower returns compared to its competitors. JHS Svendgaard Labs. has grown at ~-30.67% over the last 3yrs while peers have grown at a median rate of 25.15%
Is the promoter bullish about JHS Svendgaard Labs.?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in JHS Svendgaard Labs. is 33.85% and last quarter promoter holding is 34.56%
Are mutual funds buying/selling JHS Svendgaard Labs.?
There is Insufficient data to gauge this.